Reduced activity in an IGF system might be associated with tumour progression and poor response to treatment [26], high expression levels of IGF-IR, IR, and IGF-I mRNAs with increased survival, and high circulating IGF-1 levels with a low risk of progression [27]. This evidence concerns the gene IGF1 and neoplasm.